Maxion Therapeutics Website
Cambridge, GB · Founded 2020 · 59 employees on LinkedIn · 4 known investors
Maxion Therapeutics develops protein and antibody therapeutics using its patented KnotBody technology, which fuses cysteine-rich miniproteins (Knottins) into antibody binding loops to target ion channels and GPCRs. It focuses on first-in-class and best-in-class treatments for diseases driven by ion channel and GPCR dysfunction, including pain, autoimmune and cardiovascular conditions.
Founders & leadership
Maxion Therapeutics Website was founded in 2020 by John McCafferty and Aneesh Karatt-Vellatt.
Investors · 4
.png)
Frequently asked questions
- What does Maxion Therapeutics Website do?
- Maxion Therapeutics develops protein and antibody therapeutics using its patented KnotBody technology, which fuses cysteine-rich miniproteins (Knottins) into antibody binding loops to target ion channels and GPCRs. It focuses on first-in-class and best-in-class treatments for diseases driven by ion channel and GPCR dysfunction, including pain, autoimmune and cardiovascular conditions.
- Who founded Maxion Therapeutics Website?
- Maxion Therapeutics Website was founded by John McCafferty, Aneesh Karatt-Vellatt in 2020.
- Who are Maxion Therapeutics Website's investors?
- Maxion Therapeutics Website's investors include LifeArc Ventures, Monograph Capital Partners, General Catalyst, Solasta Ventures.
- Where is Maxion Therapeutics Website headquartered?
- Maxion Therapeutics Website is headquartered in Cambridge, GB.